Detailed information on the current drug pipeline. This report provides insight into the pipeline status of parkinson disease drugs by company and by stage as well as a summary of the latest news and developments in this area.

Provides analysis of key events and their impact on the insomnia market since 2007. Includes an event-based, indication-specific ten year forecast of both pipeline and marketed products to 2017 in the seven major markets (7MM).

Analysis of the future Huntington’s disease market with revenue forecasts of key late-stage pipeline drugs and epidemiological scenario based forecasts to 2016. Conclusions are supported by key opinion leader and industry executive comments.

This report provides up-to-date analysis of present and future market illustrated by substantial number of charts and figures. It also discusses strategies employed by key players in the industries. This is a must buy report, as it will provide you wit

Parkinson’s disease (PD) is a progressive, degenerative condition of the central nervous system that affects the way the brain coordinates body movements, including walking, talking and writing. PD affects less than 1% of the population in the se

Detailed information on the current drug pipeline. This report provides insight into the pipeline status of neuropathy drugs by company and by stage as well as a summary of the latest news and developments in this area.

In 2007, the market value of HRT for menopausal symptoms saw its first upturn since the Women’s Health initiative (WHI) study results in 2002; highly publicized findings which linked HRT to cancer and cardiovascular safety risks. The recent growt

Detailed information on the current drug pipeline. This report provides insight into the pipeline status of dementia drugs by company and by stage as well as a summary of the latest news and developments in this area.

Datamonitor believes that companies developing pipeline drugs for the depression market should concentrate resources on targeting third-line depression patients, a market with significant sales volume and few viable treatment options. GSK’s gepir

Amyotrophic lateral sclerosis (ALS) also known as Lou Gehrig’s disease in the US, Maladie de Charcot in France and Motor Neuron Disease (MND) in the UK is a progressive neuromuscular disease characterised by the progressive degeneration of mot

Detailed information on the current drug pipeline. This report provides insight into the pipeline status of epilepsy drugs by company and by stage as well as a summary of the latest news and developments in this area.

The ALS market was worth $148m in 2006 across the seven major markets. With the only approved treatment for ALS, Sanofi-Aventis’s Rilutek (riluzole), facing generic incursion in 201213, future growth in this market is dependent on the success of

Detailed information on the current drug pipeline. This report provides insight into the pipeline status of alzheimer disease drugs by company and by stage as well as a summary of the latest news and developments in this area.

The global CNS disorders market expanded by 8.0% from 2006, to reach total sales of $77.3bn in 2007. This growth has been primarily driven by treatments for AD, ADHD and Parkinson’s Disease.

With key some PD drugs expected to lose patent expiration in the near-term, visiongain predicts that the entry of new products will be inevitable. But which products will be successful and how much revenue will they generate?

The report is divided into five key sections. Chapters 2-5 present historical trends for key disease markets, key drug classes, key products and key companies. Chapter 6 outlines future CNS market trends and major growth opportunities. The data and ana

Detailed information on the current drug pipeline. This report provides insight into the pipeline status of multiple sclerosis drugs by company and by stage as well as a summary of the latest news and developments in this area.

Detailed information on the current drug pipeline. This report provides insight into the pipeline status of depression drugs by company and by stage as well as a summary of the latest news and developments in this area.

The ADHD market is currently valued at $3.85 billion and is set to increase over the next 10 years at a CAGR of 1.2%. Despite the continuing dominance of stimulant drugs, the 2002 launch of Strattera, the first non-stimulant treatment for ADHD, and the

Detailed information on the current drug pipeline. This report provides insight into the pipeline status of anxiety drugs by company and by stage as well as a summary of the latest news and developments in this area.

Detailed information on the current drug pipeline. This report provides insight into the pipeline status of pain drugs by company and by stage as well as a summary of the latest news and developments in this area.

Alzheimers disease (AD) is the third leading cause of death in recent times and with an unprecedented patient potential, this disease area attracts awareness from a broad base of stake holders.

The PD market is set to continue to grow over the next 7 years, reaching over $2.37 billion in 2013, a 39% increase from 2006 levels. Combinations, reformulations, and indication expansions will drive the majority of this growth, with key brands expect

Detailed information on the current drug pipeline. This report provides insight into the pipeline status of migraine drugs by company and by stage as well as a summary of the latest news and developments in this area.

Provides analysis of key events and their impact on the Parkinson’s disease market since 2007. Includes an event-based, indication- and country-specific 10 year forecast of both pipeline and marketed products to 2017 in the seven major markets (7

This report provides full analysis of the future Alzheimer’s disease (AD) market, with four indication- and region-specific scenario forecasts evaluating the commercial potential of pipeline and marketed drugs.

The current epilepsy market boasts a wide range of treatment options and has recently reached a state of maturity. The market value across the 7MM grew by just 2.3% from 2005 to $3.2 billion in 2006. However, imminent change to the market in the near t

Detailed information on the current drug pipeline. This report provides insight into the pipeline status of insomnia or sleep disorders drugs by company and by stage as well as a summary of the latest news and developments in this area.